Sonepcizumab

Drug Profile

Sonepcizumab

Alternative Names: ASONEP; iSONEP; LT-1009; Sonepcizumab/LT1009; Sphingomab™

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lpath
  • Developer Lpath; Pfizer
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Preclinical Diabetic retinopathy; Eye disorders; Inflammation; Multiple sclerosis
  • Discontinued Heart failure; Renal cell carcinoma

Most Recent Events

  • 15 Jun 2017 MRC Technology is now called LifeArc
  • 16 Dec 2016 Biomarkers information updated
  • 22 Mar 2016 Sonepcizumab is no longer licensed to Pfizer in USA(Lpath, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top